CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings

Video

Hans Hammers, MD, shares whether the updated CLEAR trial data would make him consider an IO-TKI regimen for patients with advanced RCC over an IO-IO regimen.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Alexander I. Spira, MD, PhD, FACP, an expert on lung cancer
Alexander I. Spira, MD, PhD, FACP, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Related Content
Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

ONCOLOGY Staff
May 13th 2023
Article

A panel of experts discuss the updated results of the phase 3 CLEAR trial presented at the 2022 International Kidney Cancer Symposium.

Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma

Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma

April 21st 2021
Article

This article reviews the results of the phase 3 KEYNOTE-581/CLEAR trial and features expert insights from trial investigators, Robert J. Motzer, MD, and Toni Choueiri, MD.